For the first time, the U.S.
Psychedelics stand at a pivotal crossroads in mental health, offering the prospect of novel therapeutic avenues to address multiple mental conditions, from treatment-resistant depression to post-traumatic...
The UK’s Medicines and Healthcare Products Regulatory Authority (MHRA) has approved a trial investigating psilocin for major depressive disorder (MDD) that will be carried out in...
PSYCH Symposium is returning at the British Museum on 6 July, when a panel of changemakers and MEPs will discuss the future of psychedelic healthcare in...
Alexander Shulgin, best known for introducing MDMA to the psychological community, also created over 230 novel psychoactive compounds and documented their effects in the book PiHKAL:...
Brazilian indigenous spiritual leader, Chief iIxiwaka Biraci Yawanawa, will be giving a keynote address on June 23 on the ‘Importance of Protecting Ayahuasca Biocultures From Commercialization,...
COMPASS Pathways and MAPS Public Benefit Corporation (PBC) have put forward a joint application for a new code to facilitate access to psychedelic therapies in the...
Psilera, a biopharmaceutical company developing next-generation mental health treatments for take-home use, announces the selection of their lead clinical candidate, PSIL-006.
A study has provided new insights into how psychedelics promote plasticity in the brain – suggesting that the antidepressant effects and the hallucinatory effects may have...
A new Ethics Council was launched at the Inaugural Summit of The World’s Leaders in Psychedelics that will work to guide industry standards and best practices.